2026年,Wegovy等重量损失药品成本上升,迫使美国雇主削减健康福利。 Rising costs of weight-loss drugs like Wegovy push U.S. employers to cut health benefits in 2026.

新的Mercer调查显示,重量损失和特殊药物,特别是GLP-1类药物(如Wegovy)成本的上涨,正促使美国大型雇主在2026年削减健康福利。 A new Mercer survey indicates that rising costs of weight-loss and specialty drugs, especially GLP-1 drugs like Wegovy, are pushing large U.S. employers to cut health benefits in 2026. 去年,77%的雇主将Wegovy列为最高成本问题,处方药成本上升8%,预计到2025年,总体健康福利成本将上升5.8%。 With 77% of employers ranking Wegovy as a top cost concern, and prescription drug costs up by 8% last year, overall health benefit costs are anticipated to rise by 5.8% in 2025. 一些雇主正在考虑调换药房福利管理人员或探索替代定价模式。 Some employers are considering switching pharmacy benefit managers or exploring alternative pricing models.